CLDN4 and breast carcinoma: On Kaplan–Meier plots for 187 breast cancer cases, the overall survival rate in the "CLDN4-high/LXRβ-high" group was slightly lower than that in the "CLDN4-low and/or LXRβ-low" group, whereas these two groups did not possess significant differences in recurrence-free survival (Fig. 7B).